Related references
Note: Only part of the references are listed.The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
Anja Irmisch et al.
CANCER CELL (2021)
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A. Wheeler et al.
CANCER CELL (2021)
Patient-derived organoid (PDO) platforms to facilitate clinical decision making
Lisa Liu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
Xing Yi Woo et al.
NATURE GENETICS (2021)
Engineering approaches for studying immune-tumor cell interactions and immunotherapy
Sarah E. Shelton et al.
ISCIENCE (2021)
Tumor organoids: Opportunities and challenges to guide precision medicine
Vivien Veninga et al.
CANCER CELL (2021)
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
Cornelis M. van Tilburg et al.
CANCER DISCOVERY (2021)
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Gadi Lalazar et al.
CANCER DISCOVERY (2021)
A pan-cancer organoid platform for precision medicine
Brian M. Larsen et al.
CELL REPORTS (2021)
Toward improved in vitro models of human cancer
Jose M. Ayuso et al.
APL BIOENGINEERING (2021)
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy
Jacqueline S. Garcia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips
Anna Herland et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Human Tumor-Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells
Jose M. Ayuso et al.
ADVANCED HEALTHCARE MATERIALS (2020)
Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Vignesh Narasimhan et al.
CLINICAL CANCER RESEARCH (2020)
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine
Krijn K. Dijkstra et al.
CELL REPORTS (2020)
Multiplexed drug testing of tumor slices using a microfluidic platform
L. F. Horowitz et al.
NPJ PRECISION ONCOLOGY (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors
Patrick D. Bhola et al.
SCIENCE SIGNALING (2020)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
3D Tumor Models and Their Use for the Testing of Immunotherapies
Nicolas Boucherit et al.
FRONTIERS IN IMMUNOLOGY (2020)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Cancer modeling meets human organoid technology
David Tuveson et al.
SCIENCE (2019)
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
Adam C. Palmer et al.
ELIFE (2019)
Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Francois M. Vallette et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer
Deena M. A. Gendoo et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
Modelling cancer in microfluidic human organs-on-chips
Alexandra Sontheimer-Phelps et al.
NATURE REVIEWS CANCER (2019)
Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems
Riccardo Barrile et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis et al.
SCIENCE (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions
Boning Gao et al.
ONCOTARGET (2017)
Functional precision cancer medicine-moving beyond pure genomics
Anthony Letai
NATURE MEDICINE (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro
Bryan A. Hassell et al.
CELL REPORTS (2017)
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
Berend Snijder et al.
LANCET HAEMATOLOGY (2017)
Non-malignant epithelial cells preferentially proliferate from nasopharyngeal carcinoma biopsy cultured under conditionally reprogrammed conditions
Fenggang Yu et al.
SCIENTIFIC REPORTS (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Tumor slice culture system to assess drug response of primary breast cancer
Kishan A. T. Naipal et al.
BMC CANCER (2016)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Elizabeth C. Townsend et al.
CANCER CELL (2016)
Epigenetic Determinants of Cancer
Stephen B. Baylin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Oliver Jonas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A technology platform to assess multiple cancer agents simultaneously within a patient's tumor
Richard A. Klinghoffer et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Biswanath Majumder et al.
NATURE COMMUNICATIONS (2015)
Precision medicine for cancer with next-generation functional diagnostics
Adam A. Friedman et al.
NATURE REVIEWS CANCER (2015)
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
Stanislas du Manoir et al.
MOLECULAR ONCOLOGY (2014)
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang et al.
CANCER RESEARCH (2013)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Tumor Engraftment in Nude Mice and Enrichment in Stroma-Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer
Ignacio Garrido-Laguna et al.
CLINICAL CANCER RESEARCH (2011)
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
Yoko S. DeRose et al.
NATURE MEDICINE (2011)
Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
Fariba Nemati et al.
CLINICAL CANCER RESEARCH (2010)
International network of cancer genome projects
Thomas J. Hudson et al.
NATURE (2010)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays
D Schrag et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
